tetano
Editor, Senior Moderator
Microbiol Immunol. 2011 Sep 7. doi: 10.1111/j.1348-0421.2011.00381.x. [Epub ahead of print]
Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: randomized controlled trial.
Uno S, Kimachi K, Kei J, Miyazaki K, Oohama A, Nishimura T, Ibaragi K, Odoh K, Kudo Y, Kino Y.
Source
The Chemo-Sero-Therapeutic Research Institute (Kaketsuken), Headquarters, Kumamoto 860-8568, Japan The Chemo-Sero-Therapeutic Research Institute (Kaketsuken), Kikuchi Research Center, Kumamoto 869-1298, Japan.
Abstract
Vaccination with the non-adjuvanted split-virion A/California/7/2009 influenza vaccine (pandemic H1N1 2009 vaccine) began in October 2009 in Japan. We studied how prior vaccination with a seasonal trivalent influenza vaccine affects the antibody response to the pandemic H1N1 2009 vaccine in healthy adult volunteers. One hundred and seventeen participants aged 22 to 62 were randomly assigned to two study groups; Group 1 (the priming group) participants were first vaccinated with the seasonal trivalent influenza vaccine followed by two separate one-dose vaccinations of the pandemic H1N1 2009 vaccine. Group 2 (the non-priming group) participants were first vaccinated with one dose of the pandemic H1N1 2009 vaccine, followed by simultaneous vaccination of the seasonal trivalent vaccine and the second dose of the pandemic H1N1 2009 vaccine. The participants of Group 2 had a seroprotection rate (SPR) of 79.7% and a seroconversion rate (SCR) of 79.7% in hemagglutination-inhibition (HI) test after the first dose of the pandemic H1N1 2009 vaccine, indicating that the pandemic H1N1 2009 vaccine is sufficiently immunogenic. On the other hand, the participants of Group 1 had a significantly weaker antibody response, with a SPR of 60.8% and a SCR of 58.5%. These results indicate that the prior vaccination with the seasonal trivalent influenza vaccine inhibited the antibody response to the pandemic H1N1 2009 vaccine. Therefore, the pandemic H1N1 2009 vaccine should have been administered prior to vaccination with the seasonal trivalent influenza vaccine.
? 2011 The Societies and Blackwell Publishing Asia Pty Ltd.
PMID:
21895745
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21895745
Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: randomized controlled trial.
Uno S, Kimachi K, Kei J, Miyazaki K, Oohama A, Nishimura T, Ibaragi K, Odoh K, Kudo Y, Kino Y.
Source
The Chemo-Sero-Therapeutic Research Institute (Kaketsuken), Headquarters, Kumamoto 860-8568, Japan The Chemo-Sero-Therapeutic Research Institute (Kaketsuken), Kikuchi Research Center, Kumamoto 869-1298, Japan.
Abstract
Vaccination with the non-adjuvanted split-virion A/California/7/2009 influenza vaccine (pandemic H1N1 2009 vaccine) began in October 2009 in Japan. We studied how prior vaccination with a seasonal trivalent influenza vaccine affects the antibody response to the pandemic H1N1 2009 vaccine in healthy adult volunteers. One hundred and seventeen participants aged 22 to 62 were randomly assigned to two study groups; Group 1 (the priming group) participants were first vaccinated with the seasonal trivalent influenza vaccine followed by two separate one-dose vaccinations of the pandemic H1N1 2009 vaccine. Group 2 (the non-priming group) participants were first vaccinated with one dose of the pandemic H1N1 2009 vaccine, followed by simultaneous vaccination of the seasonal trivalent vaccine and the second dose of the pandemic H1N1 2009 vaccine. The participants of Group 2 had a seroprotection rate (SPR) of 79.7% and a seroconversion rate (SCR) of 79.7% in hemagglutination-inhibition (HI) test after the first dose of the pandemic H1N1 2009 vaccine, indicating that the pandemic H1N1 2009 vaccine is sufficiently immunogenic. On the other hand, the participants of Group 1 had a significantly weaker antibody response, with a SPR of 60.8% and a SCR of 58.5%. These results indicate that the prior vaccination with the seasonal trivalent influenza vaccine inhibited the antibody response to the pandemic H1N1 2009 vaccine. Therefore, the pandemic H1N1 2009 vaccine should have been administered prior to vaccination with the seasonal trivalent influenza vaccine.
? 2011 The Societies and Blackwell Publishing Asia Pty Ltd.
PMID:
21895745
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21895745